CDH6

Across TCGA pan-cancer cohorts, CDH6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH6 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDH6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDH6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and HNSC are the cancer types where CDH6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.847	0.591	.007	25	view →
GBM	OS	Quartile	All	0.602	0.275	.019	5	view →
HNSC	DFS	Quartile	IV	0.414	0.980	.038	4	view →
CCRCC	DFS	Median	All	0.980	0.886	.022	3	view →
LSCC	OS	Median	All	0.920	1.000	.027	2	view →
UCEC	OS	Median	All	0.915	0.984	.043	2	view →
LUAD	OS	Median	III,IV	0.224	0.632	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH6–PDAC (DFS)

Open the PDAC breakdown →